Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-09-2016 | Original Article

Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results

Authors: Sofie Bæk Christlieb, Casper Nørgaard Strandholdt, Birgitte Brinkmann Olsen, Karen Juul Mylam, Thomas Stauffer Larsen, Anne Lerberg Nielsen, Max Rohde, Oke Gerke, Karen Ege Olsen, Michael Boe Møller, Bjarne Winther Kristensen, Niels Abildgaard, Abass Alavi, Poul Flemming Høilund-Carlsen

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2016

Abstract

Purpose

The purpose of this study was to determine the ability of dual time-point (DTP) PET/CT with ¹⁸F-FDG to discriminate between malignant and benign lymphadenopathies. The relationship between DTP FDG uptake and glucose metabolism/hypoxia markers in lymphadenopathies was also assessed.

Methods

Patients with suspected lymphoma or recently diagnosed treatment-naive lymphoma were prospectively enrolled for DTP FDG PET/CT (scans 60 min and 180 min after FDG administration). FDG-avid nodal lesions were segmented to yield volume and standardized uptake values (SUV), including SUVmax, SUVmean, cSUVmean (with partial volume correction), total lesion glycolysis (TLG) and cTLG (with partial volume correction). Expression of glucose transporter-1 (GLUT-1), hexokinase-II (HK-II), glucose-6-phosphatase (G6Pase) and hypoxia-inducible factor-1alpha (HIF-1alpha) were assessed with immunohistochemistry and enzyme activity was determined for HK and G6Pase.

Results

FDG uptake was assessed in 203 lesions (146 malignant and 57 benign). Besides volume, there were significant increases over time for all parameters, with generally higher levels in the malignant lesions. The retention index (RI) was not able to discriminate between malignant and benign lesions. Volume, SUVmax, TLG and cTLG for both scans were able to discriminate between the two groups statistically, but without complete separation. Glucose metabolism/hypoxia markers were assessed in 15 lesions. TLG and cTLG were correlated with GLUT-1 expression on the 60-min scan. RI-max and RI-mean and SUVmax, SUVmean and cSUVmean on the 60-min scan were significantly correlated with HK-II expression.

Conclusion

RI was not able to discriminate between malignant and benign lesions, but some of the SUVs were able to discriminate on the 60-min and 180-min scans. Furthermore, FDG uptake was correlated with GLUT-1 and HK-II expression.

Available only for authorised users

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68. doi:10.1200/jco.2013.54.8800.CrossRefPubMed

Kwee TC, Basu S, Saboury B, Ambrosini V, Torigian DA, Alavi A. A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging. 2011;38(6):1158–70. doi:10.1007/s00259-010-1713-9.CrossRefPubMed

Bakheet SM, Powe J. Benign causes of 18-FDG uptake on whole body imaging. Semin Nucl Med. 1998;28(4):352–8.CrossRefPubMed

Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26(10):1345–8.CrossRefPubMed

Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42(9):1412–7.PubMed

Basu S, Kung J, Houseni M, Zhuang H, Tidmarsh GF, Alavi A. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions. Q J Nucl Med Mol Imaging. 2009;53(1):9–16.PubMed

Cheng G, Alavi A, Lim E, Werner TJ, Del Bello CV, Akers SR. Dynamic changes of FDG uptake and clearance in normal tissues. Mol Imaging Biol. 2013;15(3):345–52. doi:10.1007/s11307-012-0600-0.CrossRefPubMed

Basu S, Kwee TC, Surti S, Akin EA, Yoo D, Alavi A. Fundamentals of PET and PET/CT imaging. Ann N Y Acad Sci. 2011;1228(1):1–18.CrossRefPubMed

Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B. FDG accumulation and tumor biology. Nucl Med Biol. 1998;25(4):317–22.CrossRefPubMed

10.

Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med. 1978;19(10):1154–61.PubMed

11.

Zagorska A, Dulak J. HIF-1: the knowns and unknowns of hypoxia sensing. Acta Biochim Pol. 2004;51(3):563–85.PubMed

12.

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54. doi:10.1007/s00259-014-2961-x.CrossRefPubMed

13.

Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMed

14.

Taussky HH, Shorr E. A microcolorimetric method for the determination of inorganic phosphorus. J Biol Chem. 1953;202(2):675–85.PubMed

15.

Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma. 2012;53(10):1876–81. doi:10.3109/10428194.2012.677535.CrossRefPubMed

16.

Kim J, Hong J, Kim SG, Hwang KH, Kim M, Ahn HK, et al. Prognostic value of metabolic tumor volume estimated by (18)F-FDG positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma of stage II or III disease. Nucl Med Mol Imaging. 2014;48(3):187–95. doi:10.1007/s13139-014-0280-6.CrossRefPubMedPubMedCentral

17.

Vera P, Modzelewski R, Hapdey S, Gouel P, Tilly H, Jardin F, et al. Does enhanced CT influence the biological GTV measurement on FDG-PET images? Radiother Oncol. 2013;108(1):86–90. doi:10.1016/j.radonc.2013.03.024.CrossRefPubMed

18.

Lodge MA, Chaudhry MA, Wahl RL. Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med. 2012;53(7):1041–7. doi:10.2967/jnumed.111.101733.CrossRefPubMedPubMedCentral

19.

Shinya T, Fujii S, Asakura S, Taniguchi T, Yoshio K, Alafate A, et al. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma. Ann Nucl Med. 2012;26(8):616–21. doi:10.1007/s12149-012-0619-y.CrossRefPubMed

20.

Nakayama M, Okizaki A, Ishitoya S, Sakaguchi M, Sato J, Aburano T. Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions. Ann Nucl Med. 2013;27(2):163–9. doi:10.1007/s12149-012-0669-1.CrossRefPubMed

21.

Khandani AH, Dunphy CH, Meteesatien P, Dufault DL, Ivanovic M, Shea TC. Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2009;30(8):594–601.CrossRefPubMed

22.

Watanabe Y, Suefuji H, Hirose Y, Kaida H, Suzuki G, Uozumi J, et al. 18F-FDG uptake in primary gastric malignant lymphoma correlates with glucose transporter 1 expression and histologic malignant potential. Int J Hematol. 2013;97(1):43–9.CrossRefPubMed

23.

Shim HK, Lee WW, Park SY, Kim H, Kim SE. Relationship between FDG uptake and expressions of glucose transporter type 1, type 3, and hexokinase-II in Reed-Sternberg cells of Hodgkin lymphoma. Oncol Res. 2009;17(7):331–7.CrossRefPubMed

24.

Torigian DA, Lopez RF, Alapati S, Bodapati G, Hofheinz F, van den Hoff J, et al. Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT. Hell J Nucl Med. 2011;14(1):8–14.PubMed

25.

Cheng G, Torigian DA, Zhuang H, Alavi A. When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? Eur J Nucl Med Mol Imaging. 2013;40(5):779–87. doi:10.1007/s00259-013-2343-9.CrossRefPubMed

26.

Chong EA, Torigian D, Svoboda J, Dwivedy Nasta S, Alavi A, Schuster SJ. Dual time point FDG-PET/CT imaging can distinguish between Hodgkin lymphoma and diffuse large B-cell lymphoma. Blood. 2014;124(21):1613.

27.

Yamada T, Uchida M, Kwang-Lee K, Kitamura N, Yoshimura T. Correlation of metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113(4):464–71.CrossRefPubMed

28.

Takahashi Y, Akahane T, Yamamoto D, Nakamura H, Sawa H, Nitta K, et al. Correlation between positron emission tomography findings and glucose transporter 1, 3 and L-type amino acid transporter 1 mRNA expression in primary central nervous system lymphomas. Mol Clin Oncol. 2014;2(4):525–9.PubMedPubMedCentral

29.

Hirose Y, Suefuji H, Kaida H, Hayakawa M, Hattori S, Kurata S, et al. Relationship between 2-deoxy-2-[(18)F]-fluoro-d-glucose uptake and clinicopathological factors in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55(3):520–5. doi:10.3109/10428194.2013.807509.CrossRefPubMed

30.

Shim HK, Lee WW, Park SY, Kim H, So Y, Kim SE. Expressions of glucose transporter types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin’s lymphomas. Nucl Med Biol. 2009;36(2):191–7.CrossRefPubMed

31.

Koga H, Matsuo Y, Sasaki M, Nakagawa M, Kaneko K, Hayashi K, et al. Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma. Ann Nucl Med. 2003;17(4):327–31.CrossRefPubMed

32.

Fang J, Luo XM, Yao HT, Zhou SH, Ruan LX, Yan SX. Expression of glucose transporter-1, hypoxia-inducible factor-1alpha, phosphatidylinositol 3-kinase and protein kinase B (Akt) in relation to [(18)F]fluorodeoxyglucose uptake in nasopharyngeal diffuse large B-cell lymphoma: a case report and literature review. J Int Med Res. 2010;38(6):2160–8.CrossRefPubMed

33.

Pinto A, Gattei V, Zagonel V, Aldinucci D, Degan M, De Iuliis A, et al. Hodgkin’s disease: a disorder of dysregulated cellular cross-talk. Biotherapy. 1998;10(4):309–20.CrossRefPubMed

34.

Petrasch S, Kosco M, Perez-Alvarez C, Schmitz J, Brittinger G. Proliferation of non-Hodgkin-lymphoma lymphocytes in vitro is dependent upon follicular dendritic cell interactions. Br J Haematol. 1992;80(1):21–6.CrossRefPubMed

35.

Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43(2):173–80.PubMed

36.

Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50 Suppl 1:11s–20. doi:10.2967/jnumed.108.057182.CrossRefPubMed

Title: Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results
Authors: Sofie Bæk Christlieb
Casper Nørgaard Strandholdt
Birgitte Brinkmann Olsen
Karen Juul Mylam
Thomas Stauffer Larsen
Anne Lerberg Nielsen
Max Rohde
Oke Gerke
Karen Ege Olsen
Michael Boe Møller
Bjarne Winther Kristensen
Niels Abildgaard
Abass Alavi
Poul Flemming Høilund-Carlsen
Publication date: 01-09-2016
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3385-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2016

Recurrent prostate cancer detection with anti-3-[18F]FACBC PET/CT: comparison with CT

Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer

Erratum to: Development of a nomogram combining clinical staging with 18F-FDG PET/CT image features in non-small-cell lung cancer stage I–III

PET/MRI in pancreatic and periampullary cancer: correlating diffusion-weighted imaging, MR spectroscopy and glucose metabolic activity with clinical stage and prognosis

Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC)

Highlights lecture EANM 2015: the search for nuclear medicine’s superheroes